Overall, the most commonly reported (by >75% of the respondents) tests and investigative tools were computed tomography of thorax, abdomen, and pelvis (CT TAP, reported by 96% of the respondents), the Tumour, Node, Metastasis (TNM) staging system (93% of respondents), fluorodeoxyglucose (FDG) positron emission tomography (PET) (81% of respondents), chromogranin A (81% of respondents), the Ki67 index (78% of respondents), and the World Health Organisation (WHO) classification system (78% of respondents). Here, MKI67 is linked to neoplasm.